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1. Pretraining adrninistration of 8-hydroxy-Z-di-npropylarnino-tetralin (8-OH-DPAT 0.1 rng kg-1), a 5-HTIA receptor agonist, or buspirone (1 rng kg-1), a 5-HTIA receptor partíal agonist, markedly impaired passive avoidance retention in rats 24 h later. The effect of 8-OH-DPAT was prevented by the 5-HTIA receptor antagonists, NAN-190 and WAY-100635 , at doses without any intrinsic effect. 2. N-ethoxycarbonyl-2-ethoxy-l ,2-dihydroquinoline (EEDQ 10 mg kg-1), an alkylating agent that inact'wates different G-protein coupled receptors, impaired retention performance when given 48 h pretraining. The disrupt'ive effect of EEDQ was reversed by &OH-DPAT or buspirone, given 30 min before trainrng. 3. Non-specific actions did not account for 8-OH-DPAT-induced reversal of the EEDQ effect since no significant difference in locomotor activity or in pain threshold was found between rats receiving EEDQ or EEDQ + 8-OH-DPAT.
4. When (1 mg kg-1) or WAY-100635 (0.5 mg kg-1) were given before 8-OH-DPAT to EEDQpretreated animals, the reversal by 8-OH-DPAT of EEDQ-induced retention impairment was still more pronounced. However, no EEDQ reversal by 8-OH-DPAT was found when 5-HTIA receptors were protected by WAY-100635 (10 mg kg-1) 30 min before EEDQ. 5. In the hippocampus of EEDQ-treated rats, 5-HT7 receptors were less inactivated than 5-HTIA receptors and significant increases were found in 5-HTIA but not in 5-HT7 receptor mRNA levels. Ritanserin and methiothepin (10 mg kg-1 each), antagonists with higher affinity at 5-HT7 than at 5-HTIA receptors, prevented the retention impairrnent induced by EEDQ but did not significantly protect against 5-HT7 receptor inactivation. 6. The results indicate that the facilitatory effect of 8-OH-DPAT is not mediated through 5-HTIA receptors and suggest that other 8-OH-DPAT-sensitive receptors could be involved in the dual effect of 8-OH-DPAT on passive avoidance performance in rats. Although fatigue is common among rnultiple sclerosis (MS) patients, evaluation of this symptom is difficult due to the subjectivity and variabiiity of the complaint We proposed the Fatigue Descriptive Scale (FDS) as a tool to evaluate the severity and quality of fatigue in a group of patients suffering from MS. 
